OBJECTIVE: To assess effects of chronic antidepressant drug treatment on serotonin type-1A receptor (5-HT(1A)R) binding potential (BP) in major depressive disorder. METHODS: Depressed subjects (n = 27) were imaged using PET and [(11)C]WAY-100635 at baseline and following a median of 9.4 weeks of treatment with selective serotonin reuptake inhibitor or dual reuptake inhibitor antidepressant agents. Fifteen subjects had complete pre- and post-treatment scan data. The 5-HT(1A)R BP was derived from the tissue time-radioactivity concentrations from regions-of-interest defined a priori, using a simplified reference tissue model (SRTM), and in a subset of subjects, compartmental modeling (CMOD). RESULTS: Chronic treatment had no effect on pre- or post-synaptic 5-HT(1A)R BP, as confirmed by both the SRTM and CMOD analyses. These results were unaffected by treatment response status and were consistent across brain regions. Among the 22 subjects for whom the clinical response-to-treatment was established, the treatment nonresponders (n = 7) had higher baseline BP values in the left (P = 0.01) and right orbital cortex (P = 0.02) than the responders (n = 15). CONCLUSIONS: Chronic antidepressant drug treatment did not significantly change cerebral 5-HT(1A)R binding, consistent with preclinical evidence that the alterations in serotonergic function associated with antidepressant drug administration are not accompanied by changes in 5-HT(1A)R density. Higher baseline 5-HT(1A)R binding was associated with poorer response to treatment.
OBJECTIVE: To assess effects of chronic antidepressant drug treatment on serotonin type-1A receptor (5-HT(1A)R) binding potential (BP) in major depressive disorder. METHODS: Depressed subjects (n = 27) were imaged using PET and [(11)C]WAY-100635 at baseline and following a median of 9.4 weeks of treatment with selective serotonin reuptake inhibitor or dual reuptake inhibitor antidepressant agents. Fifteen subjects had complete pre- and post-treatment scan data. The 5-HT(1A)R BP was derived from the tissue time-radioactivity concentrations from regions-of-interest defined a priori, using a simplified reference tissue model (SRTM), and in a subset of subjects, compartmental modeling (CMOD). RESULTS: Chronic treatment had no effect on pre- or post-synaptic 5-HT(1A)R BP, as confirmed by both the SRTM and CMOD analyses. These results were unaffected by treatment response status and were consistent across brain regions. Among the 22 subjects for whom the clinical response-to-treatment was established, the treatment nonresponders (n = 7) had higher baseline BP values in the left (P = 0.01) and right orbital cortex (P = 0.02) than the responders (n = 15). CONCLUSIONS: Chronic antidepressant drug treatment did not significantly change cerebral 5-HT(1A)R binding, consistent with preclinical evidence that the alterations in serotonergic function associated with antidepressant drug administration are not accompanied by changes in 5-HT(1A)R density. Higher baseline 5-HT(1A)R binding was associated with poorer response to treatment.
Authors: Ramin V Parsey; Maria A Oquendo; R Todd Ogden; Doreen M Olvet; Norman Simpson; Yung-Yu Huang; Ronald L Van Heertum; Victoria Arango; J John Mann Journal: Biol Psychiatry Date: 2005-09-09 Impact factor: 13.382
Authors: V Arango; M D Underwood; M Boldrini; H Tamir; S A Kassir; S Hsiung; J J Chen; J J Mann Journal: Neuropsychopharmacology Date: 2001-12 Impact factor: 7.853
Authors: W C Drevets; E Frank; J C Price; D J Kupfer; D Holt; P J Greer; Y Huang; C Gautier; C Mathis Journal: Biol Psychiatry Date: 1999-11-15 Impact factor: 13.382
Authors: Julie C Price; David E Kelley; Christopher M Ryan; Carolyn C Meltzer; Wayne C Drevets; Chester A Mathis; Sati Mazumdar; Charles F Reynolds Journal: Brain Res Date: 2002-02-08 Impact factor: 3.252
Authors: Carolyn Cidis Meltzer; Julie C Price; Chester A Mathis; Meryl A Butters; Scott K Ziolko; Eydie Moses-Kolko; Sati Mazumdar; Benoit H Mulsant; Patricia R Houck; Brian J Lopresti; Lisa A Weissfeld; Charles F Reynolds Journal: Neuropsychopharmacology Date: 2004-12 Impact factor: 7.853
Authors: Sean P David; Naga Venkatesha Murthy; Eugenii A Rabiner; Marcus R Munafó; Elaine C Johnstone; Robyn Jacob; Robert T Walton; Paul M Grasby Journal: J Neurosci Date: 2005-03-09 Impact factor: 6.167
Authors: Mahmoud R Hadjighassem; Mark C Austin; Bernadeta Szewczyk; Mireille Daigle; Craig A Stockmeier; Paul R Albert Journal: Biol Psychiatry Date: 2009-05-07 Impact factor: 13.382
Authors: Brian J Mickey; Francesca Ducci; Colin A Hodgkinson; Scott A Langenecker; David Goldman; Jon-Kar Zubieta Journal: J Neurosci Date: 2008-10-29 Impact factor: 6.167
Authors: V Michopoulos; M Perez Diaz; M Embree; K Reding; J R Votaw; J Mun; R J Voll; M M Goodman; M Wilson; M Sanchez; D Toufexis Journal: J Neuroendocrinol Date: 2014-02 Impact factor: 3.627
Authors: Allison C Nugent; Earle E Bain; Paul J Carlson; Alexander Neumeister; Omer Bonne; Richard E Carson; William Eckelman; Peter Herscovitch; Carlos A Zarate; Dennis S Charney; Wayne C Drevets Journal: Eur Neuropsychopharmacol Date: 2013-02-20 Impact factor: 4.600
Authors: Jeffrey M Miller; Kathleen G Brennan; Todd R Ogden; Maria A Oquendo; Gregory M Sullivan; J John Mann; Ramin V Parsey Journal: Neuropsychopharmacology Date: 2009-05-20 Impact factor: 7.853